• Shop
  • My Account
    • Cart
    • Checkout
healthtopical
  • Home
  • Diet
  • Excercise
    • Yoga
  • Drug
  • Cancer
  • Eyes
  • Stretch Marks
  • Skin
  • Hair Loss
  • News
  • Contact Us!
  • Privacy Policy
No Result
View All Result
  • Home
  • Diet
  • Excercise
    • Yoga
  • Drug
  • Cancer
  • Eyes
  • Stretch Marks
  • Skin
  • Hair Loss
  • News
  • Contact Us!
  • Privacy Policy
No Result
View All Result
healthtopical
No Result
View All Result
Home Drug

J&J to provide 10,000 more courses of TB drug to India

Loknath Das by Loknath Das
April 16, 2019
in Drug
0 0
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Image result for J&J to provide 10,000 more courses of TB drug to IndiaJohnson and Johnson has committed to provide an additional 10,000 courses of tuberculosis drug bedaquiline to India through the US Agency for International Development (USAID). This takes the number of free courses of the drug given to India to 20,000. The earlier global donation programme ended in March.

Bedaquiline is the first medicine for drug-resistant TB in nearly 50 years. It is said to be less toxic and more effective than the traditional ones.

Patent litigation

The drug is at the heart of price discussions and patent-related litigation in India. About two months ago, two TB patients had filed a patent challenge on a salt form of bedaquiline at the Mumbai Patent Office to prevent J&J from pursuing a secondary claim on the drug.

Meanwhile, a statement from J&J said that it had, through its Janssen Pharmaceutical Companies, donated more than 10,000 courses of bedaquiline in 2016 as part of a global donation programme, operated in partnership with USAID. This was with the aim of supporting and enabling the Indian government to build capacity for the medicine’s introduction, it added.

The company said it is working with the Indian government and international and local partners to improve surveillance and diagnostic capacity, train health workers in the clinical management of TB, and raise awareness about TB at the community level. It is also supporting the Make in India programme by partnering locally to produce bedaquiline for use in India and globally, it said.

The Indian government has set itself a target of ending TB by 2025, five years ahead of the global Sustainable Development Goal (SDG) target of 2030. There are an estimated 1,35,000 cases of drug-resistant TB in India every year, and currently less than 30 per cent of these patients are diagnosed and put on appropriate treatment regimen, the note said.

J&J has been in the news in India over the global recall of its faulty hip implants and the compensation its been asked to pay patients and, more recently, over health concerns involving its baby powder and shampoo.

[“source=thehindubusinessline”]

Tags: 00010CoursesdrugIndiaJ&JMoreofprovideTBto
Previous Post

Milla Jovovich Says the Keto Diet ‘Can Be Hard to Sustain,’ So She Does This Instead

Next Post

The latest diet mantra: Eating and fasting

Next Post
The latest diet mantra: Eating and fasting

The latest diet mantra: Eating and fasting

No Result
View All Result

Get Daily Update Via Mail

Follow me on Twitter

My Tweets

Like Us !

Like Us !
  • Home
  • Privacy Policy
  • Contact Us!

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Home
  • Diet
  • Excercise
    • Yoga
  • Drug
  • Cancer
  • Eyes
  • Stretch Marks
  • Skin
  • Hair Loss
  • News
  • Contact Us!
  • Privacy Policy

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In